Action mechanism elucidation of DNT, anti-prostatecancer agent from natural products
| Project/Area Number |
24592417
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Microbial Chemistry Research Foundation |
|---|
Principal Investigator |
YAMAZAKI Yohko 公益財団法人微生物化学研究会, 微生物化学研究所 沼津支所, 研究員 (80342690)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 去勢抵抗性前立腺がん / アンドロゲンレセプター / 前立腺がん / 前立腺癌 |
|---|
| Outline of Final Research Achievements |
Endocrine therapy (androgen ablation) is the main treatment for advanced prostate cancer. Despite an initial efficacy of androgen deprivation therapy, prostate cancer progress within a few years from androgen-dependent to castration- resistant (CRPC) disease in most of the patients. Although AR still plays an essential role in CRPC, AR inhibitor is only an antagonist.
We hypothesized that a new type AR inhibitor could serve as a unique therapeutic agent for prostate cancer. To identify a new type AR inhibitor, we screened cultured broths of microorganisms and found that small molecule compound N-deoxynortryptoquivaline (DNT), a novel inhibitor of AR function, showed potent inhibition against androgen-dependent proliferation of LNCaP prostate cancer cells. DNT showed significant inhibition of AR nuclear translocation and against androgen-dependent proliferation of LNCaP cells.
|
Report
(4 results)
Research Products
(7 results)
